Cartesian Therapeutics (RNAC) Price & Analysis

Compare

1,115 Followers

RNAC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.46 - $26.50

Previous CloseN/A

Volume45.37K

Average Volume (3M)64.28K

Market Cap

$294.60M

Enterprise Value$127.81M

Total Cash (Recent Filing)$160.32M

Total Debt (Recent Filing)$13.35M

Price to Earnings (P/E)―

Beta1.99

Next Earnings

Nov 06, 2025

EPS Estimate

-0.85

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.50

Shares Outstanding26,002,043

10 Day Avg. Volume53,262

30 Day Avg. Volume64,276

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue124.57

Enterprise Value/Gross Profit175.57

Enterprise Value/Ebitda-1.68

Forecast

1Y Price Target

$35.71

Price Target Upside212.42% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessDescarte-08's demonstrated efficacy in myasthenia gravis as a similarly autoantibody-mediated disease that responds to B cell depletion.

Financial PerformanceTotal 2Q25 net income was 15.9M vs. a net loss estimate of $17.5M.

Financial StabilityCartesian management stated that its current cash should fund operations into mid-2027, past the conclusion of the AURORA trial.

Bears Say

Clinical Trial RisksRisks include, but are not limited to: (1) delays in moving candidates through trials; (2) failure to generate favorable clinical data, particularly with Descartes-08 in MG.

Treatment ChallengesNon-responders to current standard of care are at high risk of organ failure and even death, with a lack of disease-modifying therapies available.

Cartesian Therapeutics News

Cartesian Therapeutics reports Q2 EPS 50c vs. 54c last year

Reports revenue $298,000, consensus $812,500. “Following the recent initiation of our pivotal Phase 3 AURORA trial of Descartes-08...

9d ago

RNAC

Cartesian Therapeutics sees cash runway into mid-2027

Cash, cash equivalents and restricted cash as of June 30, 2025 was $162.1 million and is expected to...

9d ago

RNAC

Cartesian Therapeutics announces new employment inducement grants

Cartesian Therapeutics (RNAC) announced the granting of inducement awards to two new employees. On August 4, 2025, the...

11d ago

RNAC

Promising Potential of Cartesian Therapeutics: Buy Rating Backed by Phase III AURORA Trial and Descartes-08 Performance

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on RNAC stock, giving a Buy rating...

5d ago

RNAC

Promising Developments and Strong Financial Health Support Buy Rating for Cartesian Therapeutics

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Cartesian Therapeutics. The associated price target...

8d ago

RNAC

Cartesian Therapeutics Reports Positive Q2 2025 Earnings

Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q2 earnings. Here is a breakdown of the information...

8d ago

RNAC

Optimistic Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Strong Financial Health

Analyst Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics and keeping the price target at...

9d ago

RNAC

Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis

Cartesian Therapeutics, Inc. (($RNAC)) announced an update on their ongoing clinical study. Cartesian Therapeutics, Inc. is conducting a...

1M ago

RNAC

Wedbush bullish on Cartesian Therapeutics, initiates with an Outperform

As previously reported, Wedbush initiated coverage of Cartesian Therapeutics (RNAC) with an Outperform rating and $38 price target...

1M ago

RNAC

Cartesian Therapeutics initiated with an Outperform at Wedbush

Wedbush initiated coverage of Cartesian Therapeutics (RNAC) with an Outperform rating and $38 price target Published first on...

1M ago

RNAC

Cartesian Therapeutics Holds Annual Stockholders Meeting

Cartesian Therapeutics ( ($RNAC) ) has shared an announcement. On June 13, 2025, Cartesian Therapeutics, Inc. held its...

2M ago

RNAC

Cartesian Therapeutics announces employment inducement grants

Cartesian Therapeutics (RNAC) announced the granting of inducement awards to three new employees. On June 2, 2025, the...

2M ago

RNAC

Promising Outlook for Cartesian Therapeutics: Buy Rating Backed by Advancements in Descartes-08 Trials and Strong Financial Projections

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today and...

3M ago

RNAC

Cartesian announces first participant enrolled in Phase 3 AURORA trial

Cartesian Therapeutics (RNAC) announced that the first participant has been enrolled in its Phase 3 AURORA trial of...

3M ago

RNAC

RNAC FAQ

What was Cartesian Therapeutics’s price range in the past 12 months?

Cartesian Therapeutics lowest stock price was $8.46 and its highest was $26.50 in the past 12 months.

What is Cartesian Therapeutics’s market cap?

Cartesian Therapeutics’s market cap is $294.60M.

When is Cartesian Therapeutics’s upcoming earnings report date?

Cartesian Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 82 days.

How were Cartesian Therapeutics’s earnings last quarter?

Cartesian Therapeutics released its earnings results on Aug 07, 2025. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of -$0.803 by $1.303.

Is Cartesian Therapeutics overvalued?

According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cartesian Therapeutics pay dividends?

Cartesian Therapeutics does not currently pay dividends.

What is Cartesian Therapeutics’s EPS estimate?

Cartesian Therapeutics’s EPS estimate is -0.85.

How many shares outstanding does Cartesian Therapeutics have?

Cartesian Therapeutics has 26,002,043 shares outstanding.

What happened to Cartesian Therapeutics’s price movement after its last earnings report?

Cartesian Therapeutics reported an EPS of $0.5 in its last earnings report, beating expectations of -$0.803. Following the earnings report the stock price went down -6.56%.

Which hedge fund is a major shareholder of Cartesian Therapeutics?

Currently, no hedge funds are holding shares in RNAC

Cartesian Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-938.38%

Trailing 12-Months

Asset Growth

11.83%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cartesian Therapeutics

Cartesian Therapeutics (RNAC) is a biotechnology company focused on developing RNA-based therapeutics to treat various diseases, particularly in the fields of neurology and oncology. Leveraging its proprietary platform, Cartesian Therapeutics designs and optimizes RNA molecules that can be utilized for targeted therapies. The company aims to address unmet medical needs through innovative treatment options and has a portfolio that includes preclinical and clinical-stage candidates.

Cartesian Therapeutics (RNAC) Earnings & Revenues

Historic Earnings Reports

RNAC Stock 12 Month Forecast

Average Price Target

$35.71

▲(212.42% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","43":"$43","16.75":"$16.75","25.5":"$25.5","34.25":"$34.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,16.75,25.5,34.25,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.33,14.612307692307692,16.894615384615385,19.176923076923078,21.45923076923077,23.74153846153846,26.023846153846154,28.306153846153848,30.588461538461537,32.870769230769234,35.153076923076924,37.43538461538461,39.71769230769231,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.33,14.128461538461538,15.926923076923078,17.725384615384616,19.523846153846154,21.322307692307692,23.120769230769234,24.919230769230772,26.71769230769231,28.51615384615385,30.314615384615387,32.113076923076925,33.91153846153846,{"y":35.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.33,12.227692307692308,12.125384615384615,12.023076923076923,11.920769230769231,11.818461538461538,11.716153846153846,11.613846153846154,11.511538461538462,11.409230769230769,11.306923076923077,11.204615384615385,11.102307692307692,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.47,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.11,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >